Nature chemical biology · 2020
Tetracenomycin X inhibits translation by binding within the ribosomal exit tunnel.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Osterman Ilya A, Wieland Maximiliane, Maviza Tinashe P, Lashkevich Kseniya A, Lukianov Dmitrii A, Komarova Ekaterina S, Zakalyukina Yuliya V, Buschauer Robert, Shiriaev Dmitrii I, Leyn Semen A, Zlamal Jaime E, Biryukov Mikhail V, Skvortsov Dmitry A, Tashlitsky Vadim N, Polshakov Vladimir I, Cheng Jingdong, Polikanov Yury S, Bogdanov Alexey A, Osterman Andrei L, Dmitriev Sergey E, Beckmann Roland, Dontsova Olga A, Wilson Daniel N, Sergiev Petr V
Аннотация
The increase in multi-drug resistant pathogenic bacteria is making our current arsenal of clinically used antibiotics obsolete, highlighting the urgent need for new lead compounds with distinct target binding sites to avoid cross-resistance. Here we report that the aromatic polyketide antibiotic tetracenomycin (TcmX) is a potent inhibitor of protein synthesis, and does not induce DNA damage as previously thought. Despite the structural similarity to the well-known translation inhibitor tetracycline, we show that TcmX does not interact with the small ribosomal subunit, but rather binds to the large subunit, within the polypeptide exit tunnel. This previously unappreciated binding site is located adjacent to the macrolide-binding site, where TcmX stacks on the noncanonical basepair formed by U1782 and U2586 of the 23S ribosomal RNA. Although the binding site is distinct from the macrolide antibiotics, our results indicate that like macrolides, TcmX allows translation of short oligopeptides before further translation is blocked.